Fig. 6
From: Class effects of SGLT2 inhibitors on cardiorenal outcomes
(Adapted from Ref. [60])
Baseline renal risk and composite renal outcome definitions in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trials. Horizontal dotted lines and white arrows approximate trials averaged mean eGFRs minus 1 pooled standard deviation; vertical dotted lines and white arrows approximate trials’ quartile 3 of UACR. Data displayed as mean eGFR ± standard deviation (where available); median UACR [quartile 1, quartile 3] or percent of study population with UACR < 30, > 30–300, and > 300 (depending on trial). eGFR estimated glomerular filtration rate in mL/min/1.73 m2, UACR urinary albumin-creatinine ratio in mg/g